<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Evaluation of the mesalazine-loaded nanoparticles-embedded BSA hydrogels for the ulcerative colitis treatment

Yükleniyor...
Küçük Resim

Tarih

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

ACG Publications

Erişim Hakkı

info:eu-repo/semantics/embargoedAccess

DOI

10.25135/acg.oc.171.2405.3240

Özet

Ulcerative colitis (UC) is a chronic inflammatory bowel disease mainly affecting the colon and remains a challenging disease to manage clinically with its relapsing-remitting course. Traditional treatments for this disease showed some drawbacks, including systemic toxicity and ineffective targeting of the affected colon areas. This article introduces a unique treatment method that uses mesalazine (MSZ)-loaded TPP/Chitosan nanoparticles (MSZNP)-embedded into bovine serum albumin (BSA) hydrogels (MSZNPH) for targeted intrarectal medication delivery. Additionally, conventional MSZ was integrated into BSA hydrogel (MSZH), and then, MSZH, MSZNP, and MSZNPH were characterized and compared with an emphasis on encapsulation efficiency, drug release profile, and hydrogel swelling behavior. Our findings show that MSZNPH composite technology may improve targeted administration and prolonged release of MSZ, indicating a promising new route for UC therapy with the potential to improve patient adherence and outcomes.

Açıklama

Kaynak

WoS Q Değeri

Scopus Q Değeri

Cilt

17

Sayı

3

Künye

Güler, E.; Abobakr, F. K. M.; Taşpınar, Y. M.; Bostan, M. S.; Eroğlu, M. S.; Çam, M. E. Evaluation of the mesalazine-loaded nanoparticles-embedded BSA hydrogels for the ulcerative colitis treatment (2024). Organic Communications, 17(3): 133-143.

Onay

İnceleme

Ekleyen

Referans Veren

Rights and licensing

info:eu-repo/semantics/embargoedAccess